Take2 Health Partnering with LifeStrands Genomics to Serve Singapore, Malaysia, and Vietnam
Take2 Health (“Take2”) and LifeStrands Genomics Pte. Ltd (“LifeStrands”), a diagnostic service subsidiary wholly owned by the Pathology Asia Holdings Pte. Ltd, have jointly announced a partnership to distribute the Take2 Prophecy™ Test for Nasopharyngeal Cancer (“NPC”), aiming at identifying early-stage NPC patients and thereby enabling timely diagnosis and treatments for patients.
LifeStrands offers clinical genetic services in the Southeast Asia region through its CAP-accredited laboratories in Singapore and Malaysia. With the aligned vision of applying the latest technology in medicine to innovate medical solutions, LifeStrands and Take2 share the same commitment to improving public health. Through forming the league, the test is currently available to 130 million population across LifeStrands’s regional footprints in Malaysia, Singapore, and Vietnam, via LifeStrands’s network of over 140 service locations.
The Take2 Prophecy™ Test for NPC is now offered in eight countries and regions across Asia and is expected to continuously bring immense positive impacts to the globe.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
